TY - JOUR
T1 - Gastric cancer
T2 - Current status of diagnosis and treatment
AU - Takahashi, Tsunehiro
AU - Saikawa, Yoshiro
AU - Kitagawa, Yuko
PY - 2013/3
Y1 - 2013/3
N2 - Gastric cancer is the second leading cause of death from malignant disease worldwide and most frequently discovered in advanced stages. Because curative surgery is regarded as the only option for cure, early detection of resectable gastric cancer is extremely important for good patient outcomes. Therefore, noninvasive diagnostic modalities such as evolutionary endoscopy and positron emission tomography are utilized as screening tools for gastric cancer. To date, early gastric cancer is being treated using minimally invasive methods such as endoscopic treatment and laparoscopic surgery, while in advanced cancer it is necessary to consider multimodality treatment including chemotherapy, radiotherapy, and surgery. Because of the results of large clinical trials, surgery with extended lymphadenectomy could not be recommended as a standard therapy for advanced gastric cancer. Recent clinical trials had shown survival benefits of adjuvant chemotherapy after curative resection compared with surgery alone. In addition, recent advances of molecular targeted agents would play an important role as one of the modalities for advanced gastric cancer. In this review, we summarize the current status of diagnostic technology and treatment for gastric cancer.
AB - Gastric cancer is the second leading cause of death from malignant disease worldwide and most frequently discovered in advanced stages. Because curative surgery is regarded as the only option for cure, early detection of resectable gastric cancer is extremely important for good patient outcomes. Therefore, noninvasive diagnostic modalities such as evolutionary endoscopy and positron emission tomography are utilized as screening tools for gastric cancer. To date, early gastric cancer is being treated using minimally invasive methods such as endoscopic treatment and laparoscopic surgery, while in advanced cancer it is necessary to consider multimodality treatment including chemotherapy, radiotherapy, and surgery. Because of the results of large clinical trials, surgery with extended lymphadenectomy could not be recommended as a standard therapy for advanced gastric cancer. Recent clinical trials had shown survival benefits of adjuvant chemotherapy after curative resection compared with surgery alone. In addition, recent advances of molecular targeted agents would play an important role as one of the modalities for advanced gastric cancer. In this review, we summarize the current status of diagnostic technology and treatment for gastric cancer.
KW - Chemotherapy
KW - Gastric cancer
KW - Molecular targeted therapy
KW - Radiotherapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84875246405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875246405&partnerID=8YFLogxK
U2 - 10.3390/cancers5010048
DO - 10.3390/cancers5010048
M3 - Review article
C2 - 24216698
AN - SCOPUS:84875246405
SN - 2072-6694
VL - 5
SP - 48
EP - 63
JO - Cancers
JF - Cancers
IS - 1
ER -
